The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Venetoclax with azacitidine in HR-MDS
Andrew Wei
• 10 Dec 2019
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, covers the phase 1b trial (NCT02942290) of venetoclax in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndrome (MDS). This revealed a tolerable safety profile and promising efficacy. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
